![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
KEYNOTE-426 study (European Association of Urology) View |
![]() |
KEYNOTE-426 - Pembrolizumab plus axitinib versus sunitinib for mRCC (VJOncology) View |
![]() |
Drs. Rini, Wallis on a 5-Year Analysis of KEYNOTE-426 for Advanced Clear Cell RCC (GU Oncology Now) View |
![]() |
Rana McKay, MD, discusses the design and outcomes of the Phase 3 randomized Keynote 426 study in RCC (OBRoncology) View |
![]() |
ASCO 2021 renal roundup (ecancer) View |
![]() |
2021 West Oncology APP | New Renal Cell Treatment Options Update (Total Health | Oncology) View |
![]() |
Advanced renal cell carcinoma treatment (HPR) View |
![]() |
KEYNOTE-564 study (European Association of Urology) View |
![]() |
ASCO 2020: Updates in renal cancer (ecancer) View |
![]() |
Pembrolizumab Plus Axitinib in the Second-line and Beyond for mRCC (GU Oncology Now) View |